<DOC>
	<DOC>NCT01503736</DOC>
	<brief_summary>The purpose of the study is to determine the effect and optimum dose and evaluate the safety of ferric citrate, administered three times daily (TID) immediately after meals for a total daily dose of 4 or 6 grams for 56 days, on serum phosphate (PO4) levels in subjects with end stage renal disease (ESRD).</brief_summary>
	<brief_title>A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Age&gt;18 years and has a diagnosis of ESRD On a threetimes per week hemodialysis regimen On a stable dose of a phosphatebinding agent for at least one month prior to study entry. If on vitamin D supplementation or calcitriol, must be on a stable dose for at least one month prior to study entry. Hct &gt;= 20% Serum Ca level of 8 mg/dL to 10.5 mg/dL Is pregnant or lactating Clinically significant GI disorder Has tertiary hyperparathyroidism or is immediately postoperative from a parathyroidectomy (within the first 3 months postop or the plasma Ca is &lt;7 mg/dL) ferritin&gt;800 ng/mL Unstable medical condition unsuitable for the study in the opinion of investigator Has been treated with an investigational agent within 30 days of enrollment Has a history of documented iron allergy or hemochromatosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Kidney Diseases</keyword>
	<keyword>Kidney Failure, Chronic</keyword>
	<keyword>Hyperphosphatemia</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>Renal Insufficiency, Chronic</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Phosphorus Metabolism Disorders</keyword>
</DOC>